The deal closure removes overhang uncertainty and adds a recently approved, first-in-class commercial asset (VYKAT XR) with strong early adoption potential. The $600M initial draw on the new credit facility increases leverage but is manageable given Neurocrine's cash flow profile (INGREZZA). Focus on VYKAT XR revenue trajectory and integration execution are the key near-term catalysts. Monitor next quarterly report for initial VYKAT XR sales and updated 2026 guidance reflecting the acquisition.
Price Chart
Executive Summary
Neurocrine Biosciences closed its $2.9B acquisition of Soleno Therapeutics on May 18, 2026, adding VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to its rare disease portfolio. Concurrently, Neurocrine entered into a $1.0B senior secured revolving credit facility and borrowed $600M on the closing date to fund the acquisition and for general corporate purposes. The combination of the closed transformative acquisition and the new debt facility represents a significant strategic deployment of capital.
Key Financial Metrics
Key Facts
- Acquisition of Soleno Therapeutics closed on May 18, 2026, for total equity value of $2.9B ($53.00 per share in cash).
- 88.9% of Soleno shares (46,356,114 shares) validly tendered in the offer; remaining shares converted at same $53.00 per share in the merger.
- Addition of VYKAT XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, a ~10,000-patient U.S. market.
- New $1.0B five-year senior secured revolving credit facility entered into on May 14, 2026, with an initial $600M draw.
- Total Net Leverage Ratio covenant of 3.75:1.00 (4.25:1.00 after qualifying acquisitions); minimum Interest Coverage Ratio of 2.00:1.00.
- Prior analysis on the April 6 deal announcement was bullish with an impact score of 8/10.
Financial Impact
Total equity value of $2.9 billion paid in cash, funded from available cash on hand. New $1.0 billion revolving credit facility established with $600 million drawn on closing.
Risk Factors
- Integration risk of Soleno operations and commercial launch.
- VYKAT XR market uptake may be slower than expected in the PWS indication.
- Increased leverage from the $600M draw and potential future draws; covenants tested quarterly.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-228013 |
| Document: d94926d8k.htm | 0001193125-26-228013 |
| Document: d94926dex991.htm | 0001193125-26-228013 |
| Document: 0001193125-26-228013-index-headers.html | 0001193125-26-228013 |
| Document: 0001193125-26-228013-index.html | 0001193125-26-228013 |
| Document: 0001193125-26-228013.txt | 0001193125-26-228013 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $149.50 $139.49 | ▼ −6.70% | ▼ −9.26% | $143.18 (−4.23%) |
Jul 13, 2026 11w ago | Insider Cluster | $174.10 $170.88 | ▼ −1.85% | ▼ −1.06% | $143.18 (−17.76%) |
Jul 9, 2026 12w ago | Press Release | $177.11 $171.55 | ▼ −3.14% | ▼ −2.58% | $143.18 (−19.16%) |
Jun 9, 2026 16w ago | Insider Cluster | $160.86 $156.42 | ▼ −2.76% | ▼ −6.19% | $143.18 (−10.99%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 4, 2026 17w ago | Insider Cluster | $163.88 $159.76 | ▼ −2.51% | ▼ −3.08% | $143.18 (−12.63%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access